Regulation and Function of miR-218 in Gastric Cancer Metastasis
Tie, Pan et al., PLoS Genetics
Researchers describe a negative feedback system between Robo1, a Slit receptor, and miR-218, wherein “decreased miR-218 levels eliminate Robo1 repression, which activates the Slit-Robo1 pathway through the interaction between Robo1 and Slit2, thus triggering tumor metastasis.” The authors suggest that the restoration of miR-218 supresses Robo1 espression and inhibits tumor cell invasion.
Recent Research Papers of Note
Included is a paper describing a new isobaric tandem mass tag for quantitative proteomics; a method of stopping tissue degradation for proteomics analysis; and a high-throughput de novo sequencing approach.
March 17, 2010
Bruker Paying $37.5M for Varian's ICP-MS, Lab GC, GC-QQQ-MS Businesses
The sale of the three businesses satisfies conditions set forth by the European Commission as part of its conditional approval of Agilent Technologies’ purchase of Varian.
March 15, 2010
Vermillion Eyeing Return to Nasdaq, Launches OVA1 Ovarian Cancer Test with Quest Dx
Also this week, Medicare said it is covering the test, and Vermillion reformed its scientific advisory board.
March 12, 2010
Agilent, Duquesne U Form Mass Spec Center of Excellence
The center will serve as a regional showcase for Agilent's mass spec technologies and ultimately could become a mass spec core facility for Duquesne.
March 12, 2010
NCI-CPTC, AACC Agreement Aims to Advance Proteomics in Clinical Labs
The alliance aims to take proteomics into the clinical chemistry lab and to encourage proteomics researchers to adopt procedures and processes that are routinely practiced in clinical chemistry labs.
March 12, 2010
Bigger not Always Better: Larial Proteomics Endures Homelessness, Proteomics Downturn, and Recession
The company's strategy that bigger isn't always better has so far enabled the shop to remain afloat even as other proteomic-service firms closed down or left the field.
March 12, 2010
Clinical Trial Using Proteomics Technologies for Personalized Medicine Approach to Breast Cancer
The trial is using technologies from Caris Life Sciences and George Mason University's Center for Applied Proteomics and Molecular Medicine to create proteomic profiles to determine which therapies work best for each individual patient.
March 12, 2010
Included is a method for classifying spectra to determine the prevalence of a condition; a method and system for analyzing whole proteins; and biomarkers for cancers and amyloid-associated diseases.
March 12, 2010
Proteomics Received $375.5M in NIH Funds in FY 2009, Including $55M in Stimulus Funds
The big winners in the funding sweepstakes include Rolf Apweiler, Richard Smith, projects to establish proteomics centers, and biomarker-based research.
March 05, 2010
Also at the conference, Agilent and Bruker introduced new mass specs, Thermo Fisher trumpeted its newest MS platforms, and Waters continued pushing its Acquity UPLC.
March 05, 2010
Technology Developed by Liotta and Petricoin Used to Test Chloroquine to Treat Breast Cancer
The research will use reverse-phase protein microarray technology developed by Liotta and Petricoin to create a proteomic profile of tissue samples from trial participants in order to show which protein pathways or drug targets are activated, and then determine whether chloroquine has any effect as a treatment.
March 05, 2010
